Melior Discovery in the news

< Back to main News page

Melior Signs Option Agreement with Pfizer

EXTON, Pa.--(BUSINESS WIRE)--Melior Discovery, Inc. announced today that it has signed an option
agreement that provides Pfizer Inc the exclusive right to negotiate a license to MLR-1023, Melior’s drug
candidate for Type II diabetes. In exchange, Pfizer agreed to make an undisclosed payment to Melior and
provide access to certain data it owns related to MLR-1023. In addition, Melior agreed to utilize its in-vivo
theraTRACE® indications discovery platform to evaluate the activity of selected Pfizer compounds in
partnership with Pfizer.

”This is the second collaboration initiated with Pfizer in the last 18 months and we look forward to this expansion
to our productive research and development relationship,” said Andrew Reaume, PhD, President and CEO of
Melior.

Melior Discovery Overview
Melior Discovery is leading the transformation of pharmaceutical drug repositioning with its unique theraTRACE® platform of multiplexed in vivo models. The Company is building a pipeline of drug candidates by identifying “privileged” compounds that have been discontinued by other companies and repositioning these molecules in new high potential therapeutic areas. Melior is fortunate to be working exclusively with Dr. Chris Lipinski who assists the Company in identifying ideal repositioning candidates. In addition, Melior offers pharmaceutical and biotechnology companies an opportunity to expand their development pipelines by accessing the theraTRACE® platform.

Melior Discovery is located in Exton, PA. For more information contact:
Andrew Reaume, Ph.D MBA
President and CEO
Melior Discovery
860 Springdale Drive
Exton, PA 19341
(+1) 610-280-0633 ext 239
e-mail: areaume@meliordiscovery.com

View the Archive

Back to top of page